drugset / Trial / NCT02201823
Phase I/Ib Clinical Trial of ABTL0812 in Advanced Cancer Patients
Phase 1
Completed
27 enrolled
Ability Pharmaceuticals SL
Hospital Clinic of Barcelona · collabInstitut Català d'Oncologia · collab
NaSingle-groupOpen-labelTreatment
Summary
Ability Pharmaceuticals promotes a clinical trial to determine the adequate dose of a new drug, ABTL0812, that will be administered orally daily to patients with advanced solid tumors.
Timeline
- Start
- 2014-02
- Primary completion
- 2015-03
- Completion
- 2015-04
Publications
- Polonio-Alcala E, Sole-Sanchez S, Munoz-Guardiola P, Megias-Roda E, Perez-Montoyo H, Yeste-Velasco M, Alfon J, Lizcano JM, Domenech C, Ruiz-Martinez S, Puig T. ABTL0812 enhances antitumor effect of paclitaxel and reverts chemoresistance in triple-negative breast cancer models. Cancer Commun (Lond). 2022 Jun;42(6):567-571. doi: 10.1002/cac2.12282. Epub 2022 Mar 16. No abstract available.
- Vidal L, Victoria I, Gaba L, Martin MG, Brunet M, Colom H, Cortal M, Gomez-Ferreria M, Yeste-Velasco M, Perez A, Rodon J, Sohal DPS, Lizcano JM, Domenech C, Alfon J, Gascon P. A first-in-human phase I/Ib dose-escalation clinical trial of the autophagy inducer ABTL0812 in patients with advanced solid tumours. Eur J Cancer. 2021 Mar;146:87-94. doi: 10.1016/j.ejca.2020.12.019. Epub 2021 Feb 12.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ibrilatazar | Small molecule | 500 mg | Oral |
| Subject | Ibrilatazar | Small molecule | 1300 mg | Oral |
| Subject | Ibrilatazar | Small molecule | 2000 mg | Oral |